Select Language:Translation

Immunology, Oncolysis, and Targeting Genes

Understanding LFS and TP53’s “intron 1” – Better Diagnosis for a Rare Syndrome:  “For the first time, we see LFS patients where the TP53 intron 1 rearrangement is in the germline,” says David Virshup from Duke-National University of Singapore. “We can now make a clear (and better) diagnosis (of LFS).” (01/27/2016)

CNN Money: Here is some exciting news to follow – Critical Outcome Technologies Inc. (COTI) has applied for Orphan Drug Designation for “COTI-2,” intended to treat Li-Fraumeni Syndrome. Orphan Drug status typically opens the door for expedited consideration as an approved drug treatment, along with other many other benefits. “We believe that COTI-2’s impact on cancer treatment will be far-reaching,” said Dr. Wayne Danter, President and CEO. “As we have noted in the past, we are pursuing multiple cancer indications with our lead asset, COTI-2. The prevalence of p53 gene mutations among people with LFS makes this a highly relevant target for COTI-2 and its unique mechanism of action.” “Over the past six months the Company has been working closely with MD Anderson through its various internal review committees and processes to finalize the Clinical Trial Agreement for the Phase 1 clinical trial of COTI-2 in gynecological cancers,” said Dr. Danter. “The exact number of the people affected by LFS worldwide is unclear with estimates of up to 10,000 people in the U.S., 10,000-25,000 in the United Kingdom and as many as 100,000 in the southern states of Brazil.” (12/02/2015)

Modeling Familial Cancer with Induced Pluripotent Stem Cells – Rare genetic diseases, such as LFS, make great study models because they tend to proceed from a change in a single gene. Mount Sinai’s Dr. Dung-Fang Lee and his team of researchers at the Black Family Stem Cell Institute utilized “induced pluripotent stem cells” (iPSC – “mature” stem cells) technology in his study of the development of osteosarcoma – the most common type of bone cancer in all children. His LFS-iPSC-based modeling revealed the contribution of p53, alone, to the development of osteosarcoma. “The work has implications for the future treatment or prevention of LFS-associated osteosarcoma, and possibly for all forms of bone cancer driven by p53 mutations, with H19 and p53 established now as potential targets for future drugs.” Read more here.   (April 2015)  View the video here.

Cure magazine: Consider “Going on Trial.” Many benefits can be reaped by joining a clinical trial. They can offer patients access to new and promising treatments long before they become available commercially – drugs that are immunotherapies or other types of cancer medications that may represent important advances in the field. Participation also provides patients with extra monitoring and care from the trial team, and while patients will have to live with uncertainty about the risks and benefits they face as part of a trial, they will also know they are contributing to vital scientific knowledge that may lead to new and potentially lifesaving treatments for people with all types of cancer. (07/20/2015)

NCI: Study shows promise of precision medicine for most common type of lymphomas.  “This is the first clinical study to demonstrate the importance of precision medicine in lymphomas.” (07/20/2015)

DFCI’s Science Illustrated: How does immunotherapy fight cancer? If you take the brakes off the immune system, you can unleash an attack on cancer cells… (June 2015)

Wall Street Journal: Why Gene-Editing Technology Has Scientists Excited.  Researchers are exploring the idea of treating disease by replacing the defective gene causing the trouble. (06/29/2015)

Photo: iStockphoto/Getty Images

Photo: iStockphoto/Getty Images

Researchers are developing methods to classify gliomas by their DNA which will assist doctors diagnose and plan therapies for brain cancer. As it stands now, patients are diagnosed based on the type of brain cells affected, i.e., glial cells, and on how the tumor appear to a pathologist under a microscope, when what really matters are the particular genetic mutations that caused the cancer to form.

DFCI’s Paths of Progress: Hope Blossoms – Testing of certain checkpoint inhibitors indicate that they work better in some cancers than others, but for those who have benefited from these immunotherapy agents, the benefits tend to last for years — in some cases, as it has appeared, indefinitely. These amazing responses in treating melanoma, lung cancer, glioblastoma, etc., have quickly opened doors for additional clinical studies. (Spring /Summer 2015)

NPR: Listen anytime to today’s Diane Rehm Show – “The Latest Research on Using the Body’s Own Immune System to Fight Cancer,” with Drs. Steven Rosenberg (NCI), John Sampson (Duke University Medical Center), and Suzanne Topalian (Johns Hopkins Melanoma Program). (06/02/2015)

DCFI’s Insight: New research brings better understanding of brain tumors, treatment advances. Researchers are focusing on tumor microenvironments, genomic landscapes, molecular alterations, a newly discovered protein (Eya1), and incredible advancements in treatment! (May 15, 2015)

At MD Anderson, Phil Bauman’s glioblastoma was treated with the common cold virus – three and a half years later, he remains cancer free. (My Fox Houston, May 7, 2015)

DFCI’s Insight: We now know that some viruses can cause some cancers, but here’s more on some viruses that may be able to kill cancer (May 2015):

Washington Post: Credit Dr. Steven Rosenberg’s stick-to-itiveness during his four decades at the National Cancer Institute for the successes with immunotherapy to fight cancer. (May 6, 2015)

Wall Street Journal:  “With immunotherapy, we’re treating the immune system, not the cancer…” Read about the successes in cancer treatment and view the stories of the survivors.

AACR’s 2015 Annual Meeting webcast: Dr. Robert Schreiber presents “Using genomics to personalize cancer immunotherapy.”

melanoma
DFCI’s Insight: More hope with immunotherapy for lung, breast, and ovarian cancer, as well as melanoma – from the AACR annual meeting. (April 2015)

Memorial Sloan-Kettering Cancer Center is offering a live webcast on immunotherapy, “Engaging the Immune System to Battle Cancer,” this Monday, April 27, from 6:00 to 7:30 PM ET.

DFCI’s Insight: Lung cancer treatments have been greatly enhanced with targeted therapies – doubling, tripling, and sometimes quadrupling the response rates. Watch the webchat for the latest on being precise. (April 2015)

More from the 2015 AARC Annual Meeting: an overview of the studies on combination immunotherapy for treating melanoma.

NCI Cancer Topic: Explaining Immunotherapy – treatments that restore or enhance the immune system’s ability to fight cancer. (October 2014)

DCFI’s Insight about progress with cancer vaccines – using immune system’s ability to detect and attack cancer cells:  New Immunotherapy Vaccines Show Promise in Treating Brain Tumors.  (January 2015)

Also to be presented at the American Association of Cancer Research’s Annual Meeting this month: Dysregulation of DLL4 gene expression in Li-Fraumeni syndrome and tumorigenesis. Researchers may have a strong lead on an immuno-therapeutic target in LFS and breast cancer patients.   Read the abstract here.

Dana-Farber Cancer Institute’s Insight:  New Immunotherapy Vaccines Show Promise in Treating Brain Tumors  (January 2015)

With immunotherapy, we’re treating the immune system, not the cancer…” Read about the successes in cancer treatment and view the stories of the survivors.

AACR’s What to expect in cancer immunotherapy, genomics, and prevention in 2015:  Experts Forecast Cancer Prevention and Therapies  (January 26, 2015)

American Association of Cancer Research’s CANCER RESEARCH Catalyst:  Advancing Immunotherapy for Lung Cancer  (November 2014)

WATCH! The first US Senate hearing on cancer research in 6 years – THE FIGHT AGAINST CANCER: CHALLENGES, PROGRESS, AND PROMISES, May 7th, 2014. Topics included increasing the budget for cancer research at the National Cancer Institute (“investing” versus “spending”), the relevance of genetics and basic immunology, the benefits of targeted treatments & second-line drugs based on biomarkers, and the importance of holistic system approaches. View the whole hearing or just read the statements of Senator Nelson and Senator Collins, as well as the prepared testimonies of Dr. Harold Varmus (Director of the NCI), Valerie Harper (cancer survivor), Dr. Thomas Sellers (Director of the Moffitt Cancer Center & Research Institute), Mary Dempsey (of The Patrick Dempsey Center for Cancer Hope), and Chip Kennett (cancer survivor).

NPR: Listen anytime to today’s Diane Rehm Show – “The Latest Research on Using the Body’s Own Immune System to Fight Cancer,” with Drs. Steven Rosenberg (NCI), John Sampson (Duke University Medical Center), and Suzanne Topalian (Johns Hopkins Melanoma Program). (06/02/2015)

DFCI’s Insight: Fighting cancer with patient’s own immune system has been effective in treating melanoma, prostate cancer, Hodgkin lymphoma, and certain brain tumors. (June 2015)

Dana-Farber Cancer Institute: “People with high levels of vitamin D in their bloodstream have a lower overall risk of developing colorectal cancer…:” Vitamin D Protects  (January 2015)

AACR: Zach thrives after participating in a clinical study that targeted the genetics of his lymphoma. Specificity matters.

LFS Association

We are families, like you who have been devastated by the effects of Li-Fraumeni Syndrome, a hereditary cancer predisposition syndrome. Our hopes are to educate, raise awareness and find better screening programs and treatments for LFS.

Read more...

Medical Resources

We've compiled a list of doctors available to
answer your questions, LFS support and
treatment. They specialize in many different
areas, which have been listed with their
information.

Read more...

LFS News

Newly released articles from Drs. Frederick Li and Joseph Fraumeni.

Read More...

Community Events

Team Faces of LFS Color Run
Join or support Team Faces of LFS in The Color Run™ on June 11th, 2017!

Read more...

LFS Webinars

Check out our library to watch past LFS
webinars, and to find out about
upcoming webinars!

Learn more...

LFS Awareness Brochure

Myriad Genetics is proud to partner with LFSA to launch the global LFS Education and Awareness Campaign!


Read more...